Is tremelimumab/tremelimumab approved in China?

Tremelimumab/Tremelimumab is a new cancer immunotherapy drug and a member of the anti-CTLA-4 monoclonal antibody drug class, commonly used for hepatocellular carcinoma and non-small cell lung cancer. It was approved for marketing by the United States, the European Union and other countries at the end of 2022. Therefore, it has not yet been approved for marketing in China and cannot be included in the medical insurance. Domestic patients cannot yet purchase this drug. Tremelimumab contains the active ingredient tremelimumab, a cancer drug that is used with durvalumab (another cancer drug) and a platinum-based chemotherapy drug and is given as an intravenous infusion over 60 minutes.